Stock Analysis

Insider Buying: EuroEyes International Eye Clinic Founder Bought HK$7.8m Of Shares

SEHK:1846
Source: Shutterstock

EuroEyes International Eye Clinic Limited (HKG:1846) shareholders (or potential shareholders) will be happy to see that the Founder, Jörn Jörgensen, recently bought a whopping HK$7.8m worth of stock, at a price of HK$5.19. There's no denying a buy of that magnitude suggests conviction in a brighter future, although we do note that proportionally it only increased their holding by 0.8%.

View our latest analysis for EuroEyes International Eye Clinic

The Last 12 Months Of Insider Transactions At EuroEyes International Eye Clinic

In fact, the recent purchase by Jörn Jörgensen was the biggest purchase of EuroEyes International Eye Clinic shares made by an insider individual in the last twelve months, according to our records. So it's clear an insider wanted to buy, at around the current price, which is HK$5.30. That means they have been optimistic about the company in the past, though they may have changed their mind. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. In this case we're pleased to report that the insider purchases were made at close to current prices.

Happily, we note that in the last year insiders paid HK$15m for 2.77m shares. But insiders sold 5.00k shares worth HK$29k. Overall, EuroEyes International Eye Clinic insiders were net buyers during the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
SEHK:1846 Insider Trading Volume December 7th 2023

EuroEyes International Eye Clinic is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership Of EuroEyes International Eye Clinic

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. EuroEyes International Eye Clinic insiders own about HK$1.0b worth of shares (which is 57% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

So What Does This Data Suggest About EuroEyes International Eye Clinic Insiders?

The recent insider purchase is heartening. We also take confidence from the longer term picture of insider transactions. Once you factor in the high insider ownership, it certainly seems like insiders are positive about EuroEyes International Eye Clinic. Nice! Of course, the future is what matters most. So if you are interested in EuroEyes International Eye Clinic, you should check out this free report on analyst forecasts for the company.

Of course EuroEyes International Eye Clinic may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Valuation is complex, but we're here to simplify it.

Discover if EuroEyes International Eye Clinic might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.